<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830388</url>
  </required_header>
  <id_info>
    <org_study_id>F080520002</org_study_id>
    <nct_id>NCT00830388</nct_id>
  </id_info>
  <brief_title>Ketoconazole Foam 2% for the Treatment of Versicolor</brief_title>
  <official_title>Ketoconazole Foam 2% for the Treatment of Versicolor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boni Elewski, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ten adult patients age 19 and older with a clinical diagnosis of tinea versicolor, as well as
      a positive Potassium Hydroxide (KOH) using calcofluor. Ketoconazole 2% foam will be used to
      determine its effectiveness, safety and satisfaction when used to treat tinea versicolor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives

        1. To assess the efficacy of ketoconazole 2% foam for the treatment of tinea versicolor

        2. To assess the safety of ketoconazole 2% foam for the treatment of tinea versicolor based
           on the occurrence of adverse events.

        3. To assess treatment satisfaction as rated by patients

      Study Design:

      This will be a mono-centered, single arm, open-label pilot study. Ten adult patients age 19
      and older with a clinical diagnosis of tinea versicolor, as well as a positive KOH using
      calcofluor, will be enrolled at the University of Alabama at Birmingham. There will be 4
      scheduled visits (baseline, week 1, week 2, and week 4). A target area will be identified and
      mycological and clinical assessments will be performed at this site as well as a global
      assessment of each subject. Ketoconazole 2% foam will be applied to all affected areas for 2
      weeks with a follow-up visit at week 4. Skin scraping using a disposable #15 blade for
      calcofluor/potassium hydroxide (KOH) assessment and photographs of target lesions will be
      performed at baseline, week 1, week 2, and week 4. Photographs will be taken at baseline and
      at week 4 (only if KOH is positive). Body surface area estimation of disease will also be
      performed at each visit. Evaluation of scale, hyperpigmentation/erythema, and
      hypopigmentation using a 4 point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) of the
      target area will be performed at baseline, week 1, week 2, and week 4. A global assessment
      will be conducted at each visit using the same 4 point scale. Patient questionnaires will be
      administered at baseline and week 2 to assess symptoms and satisfaction with study
      medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor</measure>
    <time_frame>4 weeks</time_frame>
    <description>Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Assess the Safety of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor Based on the Occurrence of Adverse Events.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events were used to assess safety.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Tinea Versicolor</condition>
  <arm_group>
    <arm_group_label>Ketoconazole 2% Foam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole 2% Foam</intervention_name>
    <description>Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.</description>
    <arm_group_label>Ketoconazole 2% Foam</arm_group_label>
    <other_name>Extina Foam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, aged 19 years and over.

          2. Clinical presentation of tinea versicolor.

          3. Positive KOH using calcofluor.

          4. The ability to provide informed consent (including photography release)

        Exclusion Criteria:

          1. Use of topical antifungal to the affected area in the past 30 days

          2. Use of topical steroid to the affected area in the past 14 days

          3. If female, positive urine pregnancy test at screening (female patients of childbearing
             potential must be practicing a reliable method of birth control, not be planning a
             pregnancy, not be breast-feeding during the study)

          4. Patients with a dermatologic condition in the region of the treatment site that in the
             investigator's opinion may interfere with the study results

          5. Current diagnosis of immunocompromising conditions

          6. Any medical or psychiatric condition that may interfere with treatment or compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boni E Elewski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Dermatology</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <results_first_submitted>May 1, 2012</results_first_submitted>
  <results_first_submitted_qc>August 21, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2012</results_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Boni Elewski, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>tinea versicolor</keyword>
  <keyword>ketoconazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea Versicolor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketoconazole 2% Foam</title>
          <description>Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketoconazole 2% Foam</title>
          <description>Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor</title>
        <description>Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketoconazole 2% Foam</title>
            <description>Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor</title>
          <description>Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Negative skin sample</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive skin sample</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Assess the Safety of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor Based on the Occurrence of Adverse Events.</title>
        <description>Adverse events were used to assess safety.</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketoconazole 2% Foam</title>
            <description>Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Safety of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor Based on the Occurrence of Adverse Events.</title>
          <description>Adverse events were used to assess safety.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketoconazole 2% Foam</title>
          <description>Open-label study using Ketoconazole 2% foam applied twice daily to all affected areas for 2 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wendy Cantrell</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-502-9960</phone>
      <email>wcantrell@uabmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

